Oragenics (NYSEAMERICAN:OGEN) Shares Down 1.5% – Should You Sell?

Oragenics, Inc. (NYSEAMERICAN:OGEN) shares fell 1.5% on Thursday . The company traded as low as $0.5820 and last traded at $0.6010. 28,953 shares changed hands during mid-day trading, a decline of 53% from the average session volume of 61,574 shares. The stock had previously closed at $0.61.

Oragenics Stock Down 1.5%

The stock has a market capitalization of $2.71 million, a price-to-earnings ratio of -0.03 and a beta of 1.27. The business has a 50-day simple moving average of $0.61 and a two-hundred day simple moving average of $0.76.

Oragenics (NYSEAMERICAN:OGEN) last released its earnings results on Friday, May 8th. The company reported ($0.51) earnings per share for the quarter.

Institutional Investors Weigh In On Oragenics

A number of institutional investors have recently added to or reduced their stakes in OGEN. DRW Securities LLC lifted its position in shares of Oragenics by 82.4% during the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock valued at $88,000 after acquiring an additional 50,900 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after acquiring an additional 15,338 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Oragenics during the 4th quarter valued at $26,000. Finally, Sabby Management LLC acquired a new stake in shares of Oragenics during the 3rd quarter valued at $77,000. 18.71% of the stock is currently owned by institutional investors and hedge funds.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.